JPWO2011132435A1 - 脳機能障害予防・改善用の薬剤及び飲食物 - Google Patents
脳機能障害予防・改善用の薬剤及び飲食物 Download PDFInfo
- Publication number
- JPWO2011132435A1 JPWO2011132435A1 JP2012511566A JP2012511566A JPWO2011132435A1 JP WO2011132435 A1 JPWO2011132435 A1 JP WO2011132435A1 JP 2012511566 A JP2012511566 A JP 2012511566A JP 2012511566 A JP2012511566 A JP 2012511566A JP WO2011132435 A1 JPWO2011132435 A1 JP WO2011132435A1
- Authority
- JP
- Japan
- Prior art keywords
- brain
- sepiapterin
- tetrahydrobiopterin
- cells
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
Abstract
Description
本発明に係るセピアプテリンの脳内における作用機序について、図1を用いて説明する。
本発明は、セピアプテリン又はその塩を少なくとも含有する脳機能障害の予防用、改善用、又は治療用の薬剤を広く包含する。
適用疾患については、脳内芳香族モノアミンの細胞内レベルが低下している脳機能障害であればよく、特に限定されない。
本発明は、セピアプテリン又はその塩を有効成分として少なくとも含有させた脳機能障害の予防用・改善用・治療用の飲食物をすべて包含する。
本発明に係るセピアプテリンは、公知の方法により製造でき、その製造方法は特に限定されない。
(Dulbecco’s Modified Eagle Medium;ダルベッコ培養液、以下同じ)にて継代培養し、実験に際しては、ポリリジンコートを施した96ウエルプレートに2×105/wellずつ播種し、翌日、実験開始の一時間前に血清を含まないDMEM培養液に置き換え、以下の取り込み実験に供した。
Dallas, TX 75226, USA)より提供された「hph−1」を用いた。このマウスは、テトラヒドロビオプテリン生合成機能に障害があり、脳内在テトラヒドロビオプテリンレベルが通常マウスの40〜50%であるという特徴を有する。マウスを、12時間暗−12時間明条件下で飼育し、食餌として飼育用餌(「MM-3」、株式会社船橋農場製)を、飲料水として滅菌水道水を随意に与えた。
Claims (8)
- セピアプテリンを少なくとも含有する脳機能障害の予防用又は改善用の薬剤。
- 脳神経細胞の細胞内におけるテトラヒドロビオプテリンのレベルを向上させる請求項1記載の薬剤。
- 脳内芳香族モノアミンの低下を抑制する請求項1記載の薬剤。
- 前記脳機能障害が中枢性精神障害又は中枢性運動障害である請求項1記載の薬剤。
- 前記脳機能障害がうつ、過食症、自閉症、意識集中障害、認知障害のいずれかの中枢性精神障害、若しくは筋緊張、硬直、振戦のいずれかの中枢性運動障害である請求項1記載の薬剤。
- セピアプテリンを有効成分として含有させた脳機能障害の予防用又は改善用の飲食物。
- セピアプテリンを有効量投与する脳機能障害の予防又は改善方法。
- 脳機能障害の予防用又は改善用の薬剤の製造のためのセピアプテリンの使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012511566A JP5066756B2 (ja) | 2010-04-22 | 2011-04-22 | 脳機能障害予防・改善用の薬剤及び飲食物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010098602 | 2010-04-22 | ||
JP2010098602 | 2010-04-22 | ||
PCT/JP2011/002393 WO2011132435A1 (ja) | 2010-04-22 | 2011-04-22 | 脳機能障害予防・改善用の薬剤及び飲食物 |
JP2012511566A JP5066756B2 (ja) | 2010-04-22 | 2011-04-22 | 脳機能障害予防・改善用の薬剤及び飲食物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP5066756B2 JP5066756B2 (ja) | 2012-11-07 |
JPWO2011132435A1 true JPWO2011132435A1 (ja) | 2013-07-18 |
Family
ID=44833976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012511566A Active JP5066756B2 (ja) | 2010-04-22 | 2011-04-22 | 脳機能障害予防・改善用の薬剤及び飲食物 |
Country Status (4)
Country | Link |
---|---|
US (3) | US20130197000A1 (ja) |
EP (1) | EP2562176B1 (ja) |
JP (1) | JP5066756B2 (ja) |
WO (1) | WO2011132435A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014DN09053A (ja) * | 2012-05-07 | 2015-05-22 | Shiratori Pharm | |
EP3213062B1 (en) | 2014-10-31 | 2020-02-12 | Children's Medical Center Corporation | Methods and assays relating to sepiapterin reductase inhibition |
JP7148532B2 (ja) | 2016-11-29 | 2022-10-05 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピプテリンの多形 |
KR102561697B1 (ko) | 2016-11-29 | 2023-07-28 | 피티씨 테라퓨틱스 엠피, 인크. | 세피아프테린의 다형체 및 그의 염 |
JP2020532535A (ja) * | 2017-09-01 | 2020-11-12 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
AU2019277382A1 (en) | 2018-05-30 | 2021-01-21 | Ptc Therapeutics Mp, Inc. | Methods for increasing sepiapterin plasma exposure |
CA3102105A1 (en) * | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
KR20210038848A (ko) * | 2018-05-30 | 2021-04-08 | 피티씨 테라퓨틱스 엠피, 인크. | 세피아프테린의 제약상 허용되는 염 |
AU2021209935A1 (en) * | 2020-01-24 | 2022-08-18 | Ptc Therapeutics Mp, Inc. | Methods for treating Parkinson's disease with sepiapterin |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5925323A (ja) * | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
US4550109A (en) | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
JPS61277618A (ja) * | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
JP3156112B2 (ja) | 1992-10-19 | 2001-04-16 | アサヒビール株式会社 | 癌転移抑制剤ならびに制癌剤の副作用治療剤 |
ES2177654T3 (es) | 1994-08-05 | 2002-12-16 | Suntory Ltd | Remedio contra la degeneracion espinocerebelosa. |
AU2004291082A1 (en) | 2003-11-13 | 2005-06-02 | The General Hospital Corporation | Methods for treating pain |
AU2005259961B2 (en) | 2004-06-25 | 2012-05-17 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia |
CN101171005A (zh) | 2005-05-11 | 2008-04-30 | 尼科梅德有限责任公司 | Pde4抑制剂罗氟司特与四氢生物蝶呤衍生物的组合 |
WO2008070296A2 (en) * | 2006-10-17 | 2008-06-12 | The Research Foundation For Mental Hygiene, Inc. | System and method for diagnosis and treatment of neuropsychiatric disorders |
JP2010515747A (ja) * | 2007-01-12 | 2010-05-13 | ビオマリン プハルマセウトイカル インコーポレイテッド | テトラヒドロビオプテリンプロドラッグ |
ES2906582T3 (es) | 2007-04-11 | 2022-04-19 | Biomarin Pharm Inc | Métodos para administrar tetrahidrobiopterina, composiciones asociadas y métodos de medida |
AU2008347005B2 (en) * | 2008-01-03 | 2013-10-03 | Biomarin Pharmaceutical Inc. | Pterin analog for treating BH4 responsive condition |
BRPI0923121A2 (pt) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Formas salinas de compostos orgânico |
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
IN2014DN09053A (ja) | 2012-05-07 | 2015-05-22 | Shiratori Pharm | |
EP3213062B1 (en) | 2014-10-31 | 2020-02-12 | Children's Medical Center Corporation | Methods and assays relating to sepiapterin reductase inhibition |
JP7148532B2 (ja) | 2016-11-29 | 2022-10-05 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピプテリンの多形 |
KR102561697B1 (ko) | 2016-11-29 | 2023-07-28 | 피티씨 테라퓨틱스 엠피, 인크. | 세피아프테린의 다형체 및 그의 염 |
JP2020532535A (ja) | 2017-09-01 | 2020-11-12 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
-
2011
- 2011-04-22 EP EP11771775.1A patent/EP2562176B1/en active Active
- 2011-04-22 US US13/642,639 patent/US20130197000A1/en not_active Abandoned
- 2011-04-22 JP JP2012511566A patent/JP5066756B2/ja active Active
- 2011-04-22 WO PCT/JP2011/002393 patent/WO2011132435A1/ja active Application Filing
-
2017
- 2017-11-28 US US15/823,826 patent/US20180078557A1/en not_active Abandoned
-
2019
- 2019-06-18 US US16/444,396 patent/US11173158B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20200009145A1 (en) | 2020-01-09 |
EP2562176A1 (en) | 2013-02-27 |
JP5066756B2 (ja) | 2012-11-07 |
US20130197000A1 (en) | 2013-08-01 |
US11173158B2 (en) | 2021-11-16 |
WO2011132435A1 (ja) | 2011-10-27 |
EP2562176A4 (en) | 2013-10-23 |
EP2562176B1 (en) | 2018-08-15 |
US20180078557A1 (en) | 2018-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5066756B2 (ja) | 脳機能障害予防・改善用の薬剤及び飲食物 | |
AU2009264237B2 (en) | Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue | |
WO2003006003A1 (en) | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | |
US10653641B2 (en) | Use of cannabinoids in the treatment of mental disorders | |
EP2624821B1 (en) | Combination therapy for the treatment of depression and other non-infectious diseases | |
US9555055B2 (en) | Use of albiflorin and metabolites thereof | |
US20230017155A1 (en) | Sleep improving agent | |
US20120046302A1 (en) | Methods of treating cns disorders | |
US20110257222A1 (en) | Compounds and methods for the treatment of pain and other diseases | |
KR101952443B1 (ko) | 신규한 마그네슘세리네이트 화합물 및 이의 용도 | |
US20220040186A1 (en) | Compositions and methods of treatment for neurological disorders comprising depression | |
JP2010120916A (ja) | 体内生理活性モノアミンの減少に関連して発症する精神・神経疾患の改善または治療剤 | |
US20220249453A1 (en) | Compositions and methods using trigonelline to produce intracellular nicotinamide adenine dinucleotide (nad+) for treating or preventing physiological disorders or states | |
WO2010126527A1 (en) | Methods of treating cns disorders | |
AU2021359134A1 (en) | Compositions and uses thereof | |
JP6594858B2 (ja) | メラトニン分泌調整剤、メラトニン分泌調整方法 | |
WO2014005721A1 (en) | Use of (r)-phenylpiracetam for the treatment of parkinson's disease | |
US8828453B2 (en) | Herbal-based compositions for alleviating symptoms associated with autism | |
Vegas Suárez | Characterization of buspirone effect on output basal ganglia nuclei in 6-hydroxydopamine lesioned rats with and without long-term levodopa treatment. | |
Eichenseer et al. | and surgical management | |
EP3478279A1 (en) | Combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, compositions and uses thereof in the treatment of disorders associated with protein misfolding and protein aggregations | |
JPWO2011074519A1 (ja) | 加齢性記憶障害の治療用及び予防用医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120711 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120725 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150824 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5066756 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |